Impax Asset Management Group plc Has $10.17 Million Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Impax Asset Management Group plc lifted its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 14.8% during the 4th quarter, HoldingsChannel reports. The fund owned 540,027 shares of the company’s stock after purchasing an additional 69,424 shares during the period. Impax Asset Management Group plc’s holdings in Pacira BioSciences were worth $10,174,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of PCRX. Caitlin John LLC boosted its holdings in shares of Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after acquiring an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after acquiring an additional 2,749 shares in the last quarter. Virtus Investment Advisers Inc. acquired a new stake in shares of Pacira BioSciences during the 3rd quarter valued at $98,000. China Universal Asset Management Co. Ltd. raised its position in Pacira BioSciences by 62.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock worth $134,000 after purchasing an additional 3,404 shares during the last quarter. Finally, Quest Partners LLC raised its position in Pacira BioSciences by 137.6% during the 3rd quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock worth $142,000 after purchasing an additional 5,449 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Analyst Upgrades and Downgrades

PCRX has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $39.00 target price on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Barclays lowered their target price on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and raised their target price for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Finally, Needham & Company LLC raised their target price on Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $22.78.

Pacira BioSciences Stock Performance

PCRX stock opened at $25.25 on Tuesday. The stock has a 50-day moving average price of $22.60 and a 200-day moving average price of $18.29. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.67. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The firm has a market cap of $1.17 billion, a PE ratio of -12.44 and a beta of 0.80.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.